Back on track with topsalysin in prostate cancer (PC) after a patient died in the phase IIb trial, Sophiris Bio Inc. is taking aim at a pivotal push to verify encouraging data that have turned up so far. CEO Randall Woods told BioWorld that "most people didn't believe the drug was related to the death of the patient, but unlike in the legal system, where you're innocent until proven guilty, in this case you're guilty until you can prove otherwise."